Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th
Precigen (Nasdaq: PGEN), a biopharmaceutical company focused on innovative gene and cell therapies, has announced it will release its second quarter and first half 2024 financial results on August 14, 2024. The company will host a conference call at 4:30 PM ET on the same day to discuss the results and provide a business update. Investors can access the call by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (International). Participants are advised to dial in 10-15 minutes early. Event details are available on Precigen's website in the Events & Presentations section.
Precigen (Nasdaq: PGEN), un'azienda biopharmaceutica focalizzata su terapie geniche e cellulari innovative, ha annunciato che rilascerà i suoi risultati finanziari del secondo trimestre e del primo semestre 2024 il 14 agosto 2024. L'azienda ospiterà una conference call alle 16:30 ET lo stesso giorno per discutere i risultati e fornire aggiornamenti aziendali. Gli investitori possono accedere alla chiamata componendo il numero 1-800-836-8184 (America del Nord) oppure 1-646-357-8785 (Internazionale). Si consiglia ai partecipanti di chiamare 10-15 minuti prima. I dettagli dell'evento sono disponibili sul sito web di Precigen nella sezione Eventi e Presentazioni.
Precigen (Nasdaq: PGEN), una empresa biofarmacéutica centrada en terapias génicas y celulares innovadoras, ha anunciado que publicará sus resultados financieros del segundo trimestre y del primer semestre de 2024 el 14 de agosto de 2024. La empresa llevará a cabo una conferencia telefónica a las 4:30 PM ET el mismo día para discutir los resultados y proporcionar una actualización de negocios. Los inversores pueden acceder a la llamada marcando el 1-800-836-8184 (Norteamérica) o el 1-646-357-8785 (Internacional). Se aconseja a los participantes que llamen de 10 a 15 minutos antes. Los detalles del evento están disponibles en el sitio web de Precigen en la sección de Eventos y Presentaciones.
프레시겐(나스닥: PGEN)은 혁신적인 유전자 및 세포 치료에 중점을 둔 바이오제약 회사로, 2024년 2분기 및 1학기 재무 결과를 2024년 8월 14일에 발표할 것이라고 발표했습니다. 회사는 같은 날 오후 4시 30분 ET에 재무 결과 및 사업 업데이트를 논의하기 위해 컨퍼런스 콜을 진행할 예정입니다. 투자자들은 1-800-836-8184 (북미) 또는 1-646-357-8785 (국제)로 전화하여 해당 콜에 접속할 수 있습니다. 참석자들은 10-15분 일찍 전화할 것을 권장합니다. 이벤트에 대한 자세한 정보는 프레시겐 웹사이트의 이벤트 및 프레젠테이션 섹션에서 확인할 수 있습니다.
Precigen (Nasdaq: PGEN), une entreprise biopharmaceutique axée sur les thérapies géniques et cellulaires innovantes, a annoncé qu'elle publiera ses résultats financiers pour le deuxième trimestre et le premier semestre 2024 le 14 août 2024. L'entreprise animera une conférence téléphonique à 16h30 ET le même jour pour discuter des résultats et fournir une mise à jour de l'entreprise. Les investisseurs peuvent accéder à l'appel en composant le 1-800-836-8184 (Amérique du Nord) ou le 1-646-357-8785 (International). Les participants sont invités à se connecter 10-15 minutes à l'avance. Les détails de l'événement sont disponibles sur le site Web de Precigen dans la section Événements et Présentations.
Precigen (Nasdaq: PGEN), ein biopharmazeutisches Unternehmen, das sich auf innovative Gene- und Zelltherapien konzentriert, hat angekündigt, dass es am 14. August 2024 seine Finanzergebnisse für das zweite Quartal und das erste Halbjahr 2024 veröffentlichen wird. Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen und ein Geschäftsupdate zu geben. Investoren können sich unter 1-800-836-8184 (Nordamerika) oder 1-646-357-8785 (international) in die Konferenz einwählen. Teilnehmer werden gebeten, 10-15 Minuten früher zu wählen. Details zur Veranstaltung sind auf der Website von Precigen im Abschnitt Veranstaltungen und Präsentationen verfügbar.
- None.
- None.
The conference call may be accessed by dialing 1-800-836-8184 (
Event details can be found on Precigen's website in the Events & Presentations section at investors.precigen.com/events-presentations.
Precigen: Advancing Medicine with Precision™
Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization. For more information about Precigen, visit www.precigen.com or follow us on X @Precigen, LinkedIn or YouTube.
Cautionary Statement Regarding Forward-Looking Statements
Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon the Company's current expectations and projections about future events and generally relate to plans, objectives, and expectations for the development of the Company's business, including the timing and progress of preclinical studies, clinical trials, discovery programs and related milestones, the promise of the Company's portfolio of therapies, and in particular its CAR-T and AdenoVerse therapies. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.
Investor Contact:
Steven M. Harasym
Vice President, Investor Relations
Tel: +1 (301) 556-9850
investors@precigen.com
Media Contacts:
Donelle M. Gregory
press@precigen.com
Glenn Silver
Lazar-FINN Partners
glenn.silver@finnpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/precigen-to-announce-second-quarter-and-first-half-2024-financial-results-on-august-14th-302218543.html
SOURCE Precigen, Inc.
FAQ
When will Precigen (PGEN) release its Q2 and H1 2024 financial results?
What time is Precigen's (PGEN) Q2 2024 earnings call scheduled for?
How can investors access Precigen's (PGEN) Q2 2024 earnings call?
Where can investors find details about Precigen's (PGEN) upcoming earnings event?
